Literature DB >> 20232404

Evaluation of local recurrence after treatment for hepatocellular carcinoma by contrast-enhanced ultrasonography using Sonazoid: comparison with dynamic computed tomography.

Kazue Shiozawa1, Manabu Watanabe, Ryuji Takayama, Masayoshi Takahashi, Noritaka Wakui, Kazunari Iida, Yasukiyo Sumino.   

Abstract

PURPOSE: To evaluate the effectiveness of contrast-enhanced ultrasonography (CEUS) using Sonazoid for the diagnosis of the local recurrence after treatment for hepatocellular carcinoma (HCC) by comparing it with dynamic CT.
METHODS: Seventy-one patients with 87 HCC lesions (mean +/- SD; 19.5 +/- 9.6 mm) underwent CEUS using Sonazoid and dynamic CT after radiofrequency ablation (n = 55), transcatheter arterial chemoembolization (n = 22), or radiofrequency ablation combined with transcatheter arterial chemoembolization (n = 10). Two hepatologists (observer 1; 10 years of experience, and 2; 20 years of experience) reviewed the CEUS and dynamic CT images independently and evaluated presence or absence of the local recurrence. Diagnostic performance for the local recurrence was assessed using receiver operating characteristic curve analysis.
RESULTS: The Az value for dynamic CT was significantly lower in observer 1 than 2 (p < 0.05). The sensitivity of CEUS was 79% in observer 1 and 83.9% in observer 2, and that of dynamic CT was 83.9% and 90.3%, respectively. The specificity of CEUS was 96%, and that of dynamic CT was 92%, in both observers.
CONCLUSION: This study suggests that CEUS using Sonazoid is less affected by the observer's experience and is more accurate in the diagnosis of local recurrence after treatment for HCC than dynamic CT.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20232404     DOI: 10.1002/jcu.20685

Source DB:  PubMed          Journal:  J Clin Ultrasound        ISSN: 0091-2751            Impact factor:   0.910


  8 in total

1.  Contrast-enhanced ultrasound (CEUS) follow-up after radiofrequency ablation or cryoablation of focal liver lesions: treated-area patterns and their changes over time.

Authors:  Aymeric Guibal; Caroline Bertin; Sophie Egels; Eric Savier; Philippe A Grenier; Olivier Lucidarme
Journal:  Eur Radiol       Date:  2012-11-09       Impact factor: 5.315

Review 2.  Comparative analysis of current guidelines for the treatment of hepatocellular carcinoma.

Authors:  Francesco Tovoli; Giulia Negrini; Luigi Bolondi
Journal:  Hepat Oncol       Date:  2016-03-23

3.  Diagnostic accuracy of contrast-enhanced ultrasound in assessing the therapeutic response to radio frequency ablation for liver tumors: systematic review and meta-analysis.

Authors:  Min Xuan; Fengsheng Zhou; Yan Ding; Qiaoying Zhu; Ji Dong; Hao Zhou; Jun Cheng; Xiao Jiang; Pengxi Wu
Journal:  Surg Endosc       Date:  2017-12-21       Impact factor: 4.584

4.  Contrast-enhanced ultrasound to ultrasound fusion during microwave ablation: feasibility study in a perfused porcine liver model.

Authors:  Wayne Monsky; Christina Keravnou; Michalakis Averkiou
Journal:  J Ultrasound       Date:  2019-02-27

5.  Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma.

Authors:  Yang Hai; Esika Savsani; Weelic Chong; John Eisenbrey; Andrej Lyshchik
Journal:  Abdom Radiol (NY)       Date:  2021-08-19

6.  Letter to the editor on "Perfluorobutane contrast-enhanced ultrasonography for the diagnosis of HCC: a systematic review and meta-analysis".

Authors:  Jiangfeng Wu; Lijing Ge; Lili Lu
Journal:  Abdom Radiol (NY)       Date:  2021-11-08

Review 7.  Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.

Authors:  Hitoshi Maruyama; Tadashi Sekimoto; Osamu Yokosuka
Journal:  J Gastroenterol       Date:  2015-12-22       Impact factor: 6.772

8.  Mucinous cystadenocarcinoma of the appendix in which contrast-enhanced ultrasonography was useful for assessing blood flow in a focal nodular lesion in the tumor cavity: A case report.

Authors:  Noritaka Wakui; Mitsuru Fujita; Yoshiya Yamauchi; Yuki Takeda; Nobuo Ueki; Takafumi Otsuka; Nobuyuki Oba; Shuta Nishinakagawa; Toshiko Takezoe; Junko Hiroyoshi; Yoshiharu Kono; Seiichiro Katahira; Masami Minagawa; Yasushi Takeda; Saori Shiono; Tatsuya Kojima
Journal:  Exp Ther Med       Date:  2013-04-30       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.